In vivo lesion imaging detection is a specialized preclinical testing service that enables non-invasive visualization, localization, and quantitative assessment of pathological lesions in living animals using advanced modalities such as micro-CT, MRI, PET, ultrasound, and optical imaging. Accredited third-party laboratories perform these studies to support oncology research, drug efficacy evaluation, safety assessment, and translational medicine, delivering longitudinal data that reduces animal usage while improving statistical power.
Technical Overview
In vivo lesion imaging detection refers to the use of non-invasive or minimally invasive imaging technologies to detect, localize, and characterize focal pathological changes—such as tumors, inflammatory foci, necrotic regions, vascular abnormalities, and structural degeneration—within the bodies of living animals. Unlike terminal histopathology, in vivo imaging allows the same animal to be scanned repeatedly at multiple time points, enabling true longitudinal monitoring of lesion onset, progression, and response to intervention.
Typical modalities include micro-computed tomography (micro-CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), high-frequency ultrasound, and optical imaging (bioluminescence and fluorescence). Each modality offers a distinct combination of spatial resolution, tissue contrast, functional information, and throughput, and multi-modal fusion protocols are frequently designed to combine anatomical and molecular findings.
Studies are typically conducted under Good Laboratory Practice (GLP) principles aligned with OECD guidelines, within quality management systems consistent with ISO/IEC 17025, and in accordance with animal welfare requirements defined by institutional animal care and use committee (IACUC) protocols, Directive 2010/63/EU, and national laboratory animal care standards such as the applicable GB series. Imaging equipment performance verification and dose metrology follow recognized IEC and NEMA measurement conventions where applicable.
Testing Samples
Small Laboratory Rodents
Mice and rats are the most common subjects, including syngeneic tumor models, patient-derived xenografts (PDX), orthotopic implantation models, genetically engineered spontaneous tumor models, and chemically or surgically induced disease models. Rodent imaging typically requires isoflurane inhalation anesthesia with physiological monitoring of respiration and body temperature throughout acquisition.
Large Animal Models
Rabbits, guinea pigs, dogs, miniature pigs, and non-human primates are used when lesion size, anatomy, or translational relevance demands a larger host. These species are common in orthopedic, cardiovascular, and neurodegenerative lesion studies, and imaging protocols are adapted for clinical-grade scanners or dedicated large-bore preclinical systems.
Disease and Lesion Model Categories
- Oncological lesions: subcutaneous and orthotopic tumors, metastatic nodules, leukemia infiltrates, and residual disease after treatment
- Musculoskeletal lesions: bone defects, osteolysis, osteoarthritis, osteoporotic micro-fractures, and implant-related bone remodeling
- Cardiovascular lesions: atherosclerotic plaques, aneurysms, myocardial infarction zones, and vascular stenosis
- Neurological lesions: cerebral ischemia, hemorrhage, demyelination, gliosis, and neurodegenerative atrophy
- Inflammatory and infectious foci: abscesses, granulomas, arthritis joints, and fibrotic nodules
- Hepatic, renal, and pulmonary lesions: nodules, cysts, fibrosis, and metastatic deposits in visceral organs
Ex Vivo and Explant Validation Specimens
Following terminal imaging, excised organs, bones, or tumor specimens may be scanned at high resolution ex vivo and correlated with histopathology, providing ground-truth validation of the in vivo measurements.
Testing Items
Depending on the study objective, the following quantitative and qualitative endpoints are routinely reported:
- Lesion detection, confirmation, and three-dimensional localization within the animal body
- Lesion number, diameter, volume, and morphology measured from reconstructed image data
- Tumor growth curves and tumor growth inhibition (TGI) calculated from serial scans
- Bone microarchitecture indices: trabecular thickness, trabecular separation, bone volume fraction, and bone mineral density
- Soft-tissue contrast characterization, including necrotic core identification and edema mapping
- Functional and metabolic endpoints: standardized uptake values (SUV) from PET, perfusion parameters, and hemodynamic flow indices
- Contrast-enhanced vascularization, vessel density, and permeability assessment
- Metastasis burden scoring in lung, liver, lymph node, and bone compartments
- Longitudinal lesion progression and therapeutic response tracking in the same subject
- Image-based safety findings, such as incidental nodules or injection-site reactions observed during general toxicity studies
Testing Methods
Micro-Computed Tomography (Micro-CT)
High-resolution X-ray imaging, often coupled with iodinated or nanoparticle contrast agents, is used to evaluate bone lesions, lung nodules, vascular networks, and soft-tissue masses. Volumetric reconstruction enables direct three-dimensional morphometry with spatial resolution down to the micrometer scale for ex vivo specimens.
Magnetic Resonance Imaging (MRI)
High-field preclinical MRI (commonly 3 T to 9.4 T systems) provides excellent soft-tissue contrast for brain, hepatic, muscular, and cardiac lesions. Sequences such as T1-weighted, T2-weighted, diffusion-weighted, and contrast-enhanced imaging support lesion delineation, edema quantification, and tissue characterization without ionizing radiation.
PET and SPECT Molecular Imaging
Radiotracer-based imaging with agents such as fluorine-18 labeled glucose analogues quantifies glucose metabolism, receptor expression, or cell proliferation within lesions. PET/CT or SPECT/CT fusion delivers co-registered anatomical and molecular data, which is particularly valuable for confirming viable tumor tissue and detecting occult metastases.
High-Frequency Ultrasound
Real-time B-mode, Doppler, and contrast-enhanced ultrasound are applied to measure lesion dimensions, cardiac function, blood flow velocity, and vascularization in abdominal and subcutaneous structures. Ultrasound is radiation-free and well suited for frequent longitudinal monitoring.
Optical Imaging
Bioluminescence imaging of luciferase-expressing tumor cells and fluorescence imaging of labeled probes or reporter agents enable rapid whole-body screening for lesion burden and cell trafficking with high sensitivity, primarily in small rodents.
Image Processing, Quantification, and Reporting
Acquired datasets undergo standardized reconstruction, attenuation correction where applicable, region-of-interest segmentation, and three-dimensional analysis using validated software pipelines. Reports typically include representative images at each time point, quantitative endpoint tables, individual animal data, group statistics, and interpretation relative to the study hypothesis. All procedures are documented under controlled protocols with anesthesia, animal warming, and monitoring records retained for audit.
Applications
In vivo lesion imaging detection supports a broad range of research, development, and regulatory activities:
- Preclinical oncology: anti-tumor efficacy studies, dose-response characterization, and combination therapy evaluation
- Drug safety and toxicology: detection of treatment-induced nodules, fibrosis, or organ changes during repeat-dose studies
- Medical device and biomaterial evaluation: bone implant integration, degradation tracking, and wear-particle induced osteolysis assessment
- Regenerative medicine: monitoring of scaffolds, stem cell engraftment, and tissue engineered constructs
- Metabolic and cardiovascular research: plaque progression, infarct size measurement, and hepatic steatosis quantification
- Neuroscience: stroke volume tracking, neurodegeneration monitoring, and brain lesion localization
- Infectious disease and inflammation research: abscess monitoring, arthritis scoring, and anti-inflammatory efficacy testing
- Publication and regulatory submission support: objective imaging endpoints strengthen study reports, manuscripts, and investigational application dossiers
FAQ
What animal species can undergo in vivo lesion imaging?
Mice and rats are the most widely imaged species, while rabbits, dogs, pigs, and non-human primates can be accommodated on appropriately sized systems. The selected modality and protocol are matched to the species, lesion type, and required resolution.
Is anesthesia required, and is the procedure safe?
Most scans require light inhalation anesthesia with isoflurane to eliminate motion artifacts and minimize stress. Physiological monitoring and warming are provided throughout, and imaging modalities such as ultrasound and MRI avoid ionizing radiation entirely.
Can the same animal be scanned more than once?
Yes. Repeated scanning of the same subject is a principal advantage of in vivo imaging, allowing each animal to serve as its own control and substantially reducing the number of animals required compared with terminal cross-sectional sampling.
What spatial and temporal resolution can be expected?
Micro-CT can reach micrometer-level resolution for bone and ex vivo specimens, high-field MRI typically resolves structures in the range of tens to one hundred micrometers in vivo, and PET provides millimeter-scale metabolic imaging. Scan durations generally range from a few minutes for optical imaging to thirty minutes or more for comprehensive MRI protocols.
How are imaging findings validated?
Quantitative in vivo results are routinely corroborated by ex vivo high-resolution scanning, gross necropsy observation, and histopathological examination, ensuring that imaging endpoints are anchored to morphological ground truth.
How should a study be initiated?
Sponsors typically provide the animal model description, lesion background, study objectives, and desired time points. The laboratory then designs a modality-specific imaging protocol, confirms ethical approval status, and issues a study plan detailing acquisition parameters, quantification endpoints, and the reporting schedule.
